Replimune Group Inc — 四半期キャッシュフロー (NASDAQ:REPL) | MetaTrader

チャート全体を表示

Financials

概要明細書統計

総資産 551.33 M469.51 M389.45 M333.59 M 負債合計 135.49 M132.79 M126.11 M123.05 M 純資産合計 415.84 M336.71 M263.34 M210.54 M 負債および純資産合計 551.33 M469.51 M389.45 M333.59 M 有利子負債合計 49.18 M49.61 M50.05 M50.49 M 純負債 -434.63 M-353.73 M-273.6 M-218.65 M

ニュース

Replimune stock collapses 64% following FDA rejection

Undercovered Stocks: Zscaler, Aeluma, Devon Energy, And More

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.63%

FDA Rejection Sparks Questions On Replimune Drug Approval Path - Replimune Group (NASDAQ:REPL)

原油5％上昇、ファスナルは第1四半期決算を受け下落

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

ダウが350ポイント以上下落、ゴールドマン好決算も相場支えきれず

Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives (REPL)

FDA Review Looms As Replimune Faces Weak Technical Setup - Replimune Group (NASDAQ:REPL)

Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback (NASDAQ:IOVA)

RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer